Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era
Citations Over TimeTop 25% of 2006 papers
Abstract
Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.
Related Papers
- → Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia(2007)27 cited
- → Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report(2004)15 cited
- → Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country(2010)10 cited
- → Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia(2004)9 cited
- Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate(2007)